2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by COVINGTON & BURLING LLP.
Open official filingSource-reported fields
Literal source text
Biopharmaceutical innovation and intellectual property policy issues; patent subject matter; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Skinny Labels, Big Savings Act (S. 43); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.
Literal federal measure citations: S. 1097, S. 43, S. 1096, S. 1041
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).
Literal federal measure citations: H.R. 1262, S. 932, S. 1095, S. 1040, S. 1041, S. 1097, S. 1096, S. 832, H.R.1492, S. 705, S. 43
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
